Aldeyra Therapeutics, Inc.ALDXNASDAQ
LOADING
|||
Operating Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
21.32%
↑ 505% above average
Average (39q)
-5.26%
Historical baseline
Range
High:38.45%
Low:-91.70%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 21.32% |
| Q2 2025 | 2.48% |
| Q1 2025 | 37.10% |
| Q4 2024 | -2.73% |
| Q3 2024 | 10.39% |
| Q2 2024 | -91.70% |
| Q1 2024 | -54.05% |
| Q4 2023 | 36.15% |
| Q3 2023 | 7.66% |
| Q2 2023 | 38.45% |
| Q1 2023 | -22.68% |
| Q4 2022 | 7.36% |
| Q3 2022 | 16.54% |
| Q2 2022 | -7.47% |
| Q1 2022 | -7.01% |
| Q4 2021 | 0.24% |
| Q3 2021 | -6.18% |
| Q2 2021 | -34.27% |
| Q1 2021 | -13.61% |
| Q4 2020 | -13.64% |
| Q3 2020 | -18.06% |
| Q2 2020 | 26.28% |
| Q1 2020 | 25.26% |
| Q4 2019 | 32.19% |
| Q3 2019 | -38.49% |
| Q2 2019 | -26.74% |
| Q1 2019 | 2.35% |
| Q4 2018 | -1.35% |
| Q3 2018 | -19.43% |
| Q2 2018 | -7.95% |
| Q1 2018 | -20.49% |
| Q4 2017 | -40.52% |
| Q3 2017 | 5.93% |
| Q2 2017 | -4.61% |
| Q1 2017 | -9.52% |
| Q4 2016 | 2.58% |
| Q3 2016 | -11.15% |
| Q2 2016 | 13.49% |
| Q1 2016 | -14.47% |
| Q4 2015 | -29.99% |